Details of the Drug

General Information of Drug (ID: DMFN07X)

Drug Name
Nilutamide
Synonyms
Anandron; Nilandron; Nilandrone; Nilutamida; Nilutamidum; Aventis Behring Brand of Nilutamide; Aventis Brand of Nilutamide; Hoechst Brand of Nilutamide; Nilutamida [Spanish]; Nilutamidum [Latin]; N 8534; RU 23908; Anandron (TN); RU 23908-10; RU-23908; Nilutamide (USAN/INN); Nilutamide [USAN:BAN:INN]; Nilutamide [USAN:INN:BAN]; 1-(3'-Trifluoromethyl-4'-nitrophenyl)-4,4-dimethylimidazolidine-2,5-dione; 5,5-Dimethyl-3-(4-nitro-3-(trifluoromethyl)phenyl)-2,4-imidazolidinedione; 5,5-Dimethyl-3-(alpha,alpha,alpha-trifluoro-4-nitro-m-tolyl)hydantoin; 5,5-Dimethyl-3-[4-nitro-3-(trifluoromethyl)phenyl]-2,4-imidazolidinedione; 5,5-dimethyl-3-(4-nitro-3-(trifluoromethyl)phenyl)-2,4-imidazolidinedione; 5,5-dimethyl-3-[4-nitro-3-(trifluoromethyl)phenyl]imidazolidine-2,4-dione
Indication
Disease Entry ICD 11 Status REF
Prostate cancer 2C82.0 Approved [1], [2]
Therapeutic Class
Anticancer Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 317.22
Topological Polar Surface Area (xlogp) 2
Rotatable Bond Count (rotbonds) 1
Hydrogen Bond Donor Count (hbonddonor) 1
Hydrogen Bond Acceptor Count (hbondacc) 7
ADMET Property
Bioavailability
99% of drug becomes completely available to its intended biological destination(s) [3]
Half-life
The concentration or amount of drug in body reduced by one-half in 38.0 - 59.1 hours [4]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 13.5098 micromolar/kg/day [5]
Chemical Identifiers
Formula
C12H10F3N3O4
IUPAC Name
5,5-dimethyl-3-[4-nitro-3-(trifluoromethyl)phenyl]imidazolidine-2,4-dione
Canonical SMILES
CC1(C(=O)N(C(=O)N1)C2=CC(=C(C=C2)[N+](=O)[O-])C(F)(F)F)C
InChI
InChI=1S/C12H10F3N3O4/c1-11(2)9(19)17(10(20)16-11)6-3-4-8(18(21)22)7(5-6)12(13,14)15/h3-5H,1-2H3,(H,16,20)
InChIKey
XWXYUMMDTVBTOU-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
4493
ChEBI ID
CHEBI:7573
CAS Number
63612-50-0
DrugBank ID
DB00665
TTD ID
D0SN9T
INTEDE ID
DR1158
ACDINA ID
D00469

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Androgen receptor (AR) TTS64P2 ANDR_HUMAN Antagonist [6]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Mephenytoin 4-hydroxylase (CYP2C19) DEGTFWK CP2CJ_HUMAN Substrate [7]
NADPH-cytochrome P450 reductase (CPR) DE3N2FM NCPR_HUMAN Substrate [8]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Prostate cancer
ICD Disease Classification 2C82.0
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Androgen receptor (AR) DTT AR 2.13E-01 -0.07 -0.11
Mephenytoin 4-hydroxylase (CYP2C19) DME CYP2C19 1.00E-03 1.34E-01 1.10E+00
NADPH-cytochrome P450 reductase (CPR) DME POR 2.29E-03 2.74E-01 7.46E-01
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Nilutamide
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Enzalutamide DMGL19D Moderate Increased metabolism of Nilutamide caused by Enzalutamide mediated induction of CYP450 enzyme. Prostate cancer [2C82] [37]
Coadministration of a Drug Treating the Disease Different from Nilutamide (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Remdesivir DMBFZ6L Moderate Increased risk of hepatotoxicity by the combination of Nilutamide and Remdesivir. 1D6YCoronavirus Disease 2019 [1D6YCoronavirus Disease 2019] [38]
Ivosidenib DM8S6T7 Major Increased risk of prolong QT interval by the combination of Nilutamide and Ivosidenib. Acute myeloid leukaemia [2A60] [39]
Midostaurin DMI6E0R Moderate Increased risk of prolong QT interval by the combination of Nilutamide and Midostaurin. Acute myeloid leukaemia [2A60] [40]
Idarubicin DMM0XGL Moderate Increased risk of prolong QT interval by the combination of Nilutamide and Idarubicin. Acute myeloid leukaemia [2A60] [40]
Daunorubicin DMQUSBT Moderate Increased risk of prolong QT interval by the combination of Nilutamide and Daunorubicin. Acute myeloid leukaemia [2A60] [40]
Arn-509 DMT81LZ Moderate Increased metabolism of Nilutamide caused by Arn-509 mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [40]
Gilteritinib DMWQ4MZ Moderate Increased risk of prolong QT interval by the combination of Nilutamide and Gilteritinib. Acute myeloid leukaemia [2A60] [40]
Oliceridine DM6MDCF Moderate Increased risk of prolong QT interval by the combination of Nilutamide and Oliceridine. Acute pain [MG31] [40]
Metronidazole DMTIVEN Minor Increased risk of prolong QT interval by the combination of Nilutamide and Metronidazole. Amoebiasis [1A36] [38]
Ivabradine DM0L594 Major Increased risk of ventricular arrhythmias by the combination of Nilutamide and Ivabradine. Angina pectoris [BA40] [40]
Bepridil DM0RKS4 Major Increased risk of prolong QT interval by the combination of Nilutamide and Bepridil. Angina pectoris [BA40] [41]
Dronedarone DMA8FS5 Major Increased risk of prolong QT interval by the combination of Nilutamide and Dronedarone. Angina pectoris [BA40] [41]
Bedaquiline DM3906J Major Increased risk of prolong QT interval by the combination of Nilutamide and Bedaquiline. Antimicrobial drug resistance [MG50-MG52] [42]
Cilostazol DMZMSCT Moderate Increased risk of prolong QT interval by the combination of Nilutamide and Cilostazol. Arterial occlusive disease [BD40] [40]
Posaconazole DMUL5EW Moderate Increased risk of prolong QT interval by the combination of Nilutamide and Posaconazole. Aspergillosis [1F20] [40]
Levalbuterol DM5YBO1 Moderate Increased risk of ventricular arrhythmias by the combination of Nilutamide and Levalbuterol. Asthma [CA23] [43]
Terbutaline DMD4381 Moderate Increased risk of ventricular arrhythmias by the combination of Nilutamide and Terbutaline. Asthma [CA23] [44]
Pirbuterol DMI5678 Moderate Increased risk of prolong QT interval by the combination of Nilutamide and Pirbuterol. Asthma [CA23] [44]
Salbutamol DMN9CWF Moderate Increased risk of ventricular arrhythmias by the combination of Nilutamide and Salbutamol. Asthma [CA23] [43]
Formoterol DMSOURV Moderate Increased risk of ventricular arrhythmias by the combination of Nilutamide and Formoterol. Asthma [CA23] [44]
Lisdexamfetamine DM6W8V5 Moderate Increased risk of prolong QT interval by the combination of Nilutamide and Lisdexamfetamine. Attention deficit hyperactivity disorder [6A05] [40]
Desipramine DMT2FDC Moderate Increased risk of prolong QT interval by the combination of Nilutamide and Desipramine. Attention deficit hyperactivity disorder [6A05] [40]
Ofloxacin DM0VQN3 Moderate Increased risk of prolong QT interval by the combination of Nilutamide and Ofloxacin. Bacterial infection [1A00-1C4Z] [40]
Clarithromycin DM4M1SG Moderate Increased risk of prolong QT interval by the combination of Nilutamide and Clarithromycin. Bacterial infection [1A00-1C4Z] [40]
Sulfamethoxazole DMB08GE Minor Increased risk of prolong QT interval by the combination of Nilutamide and Sulfamethoxazole. Bacterial infection [1A00-1C4Z] [41]
Sparfloxacin DMB4HCT Major Increased risk of prolong QT interval by the combination of Nilutamide and Sparfloxacin. Bacterial infection [1A00-1C4Z] [45]
Gemifloxacin DMHT34O Moderate Increased risk of prolong QT interval by the combination of Nilutamide and Gemifloxacin. Bacterial infection [1A00-1C4Z] [40]
Norfloxacin DMIZ6W2 Moderate Increased risk of prolong QT interval by the combination of Nilutamide and Norfloxacin. Bacterial infection [1A00-1C4Z] [40]
Levofloxacin DMS60RB Moderate Increased risk of prolong QT interval by the combination of Nilutamide and Levofloxacin. Bacterial infection [1A00-1C4Z] [40]
Lomefloxacin DMVRH9C Moderate Increased risk of prolong QT interval by the combination of Nilutamide and Lomefloxacin. Bacterial infection [1A00-1C4Z] [40]
Telithromycin DMZ4P3A Moderate Increased risk of prolong QT interval by the combination of Nilutamide and Telithromycin. Bacterial infection [1A00-1C4Z] [40]
Retigabine DMGNYIH Moderate Increased risk of prolong QT interval by the combination of Nilutamide and Retigabine. Behcet disease [4A62] [40]
Pexidartinib DMS2J0Z Major Increased risk of hepatotoxicity by the combination of Nilutamide and Pexidartinib. Bone/articular cartilage neoplasm [2F7B] [46]
Loperamide DMOJZQ9 Moderate Increased risk of prolong QT interval by the combination of Nilutamide and Loperamide. Bowel habit change [ME05] [47]
Lapatinib DM3BH1Y Moderate Increased risk of prolong QT interval by the combination of Nilutamide and Lapatinib. Breast cancer [2C60-2C6Y] [40]
Tamoxifen DMLB0EZ Moderate Increased risk of prolong QT interval by the combination of Nilutamide and Tamoxifen. Breast cancer [2C60-2C6Y] [40]
Bosutinib DMTI8YE Moderate Increased risk of prolong QT interval by the combination of Nilutamide and Bosutinib. Breast cancer [2C60-2C6Y] [40]
PF-04449913 DMSB068 Moderate Increased risk of prolong QT interval by the combination of Nilutamide and PF-04449913. Chronic myelomonocytic leukaemia [2A40] [40]
Olodaterol DM62B78 Moderate Increased risk of ventricular arrhythmias by the combination of Nilutamide and Olodaterol. Chronic obstructive pulmonary disease [CA22] [44]
Vilanterol DMF5EK1 Moderate Increased risk of prolong QT interval by the combination of Nilutamide and Vilanterol. Chronic obstructive pulmonary disease [CA22] [43]
Salmeterol DMIEU69 Moderate Increased risk of ventricular arrhythmias by the combination of Nilutamide and Salmeterol. Chronic obstructive pulmonary disease [CA22] [44]
Indacaterol DMQJHR7 Moderate Increased risk of ventricular arrhythmias by the combination of Nilutamide and Indacaterol. Chronic obstructive pulmonary disease [CA22] [44]
Arformoterol DMYM974 Moderate Increased risk of ventricular arrhythmias by the combination of Nilutamide and Arformoterol. Chronic obstructive pulmonary disease [CA22] [44]
Isoproterenol DMK7MEY Moderate Increased risk of ventricular arrhythmias by the combination of Nilutamide and Isoproterenol. Conduction disorder [BC63] [43]
Halothane DM80OZ5 Moderate Increased risk of prolong QT interval by the combination of Nilutamide and Halothane. Corneal disease [9A76-9A78] [40]
Propofol DMB4OLE Moderate Increased risk of prolong QT interval by the combination of Nilutamide and Propofol. Corneal disease [9A76-9A78] [48]
Sevoflurane DMC9O43 Moderate Increased risk of prolong QT interval by the combination of Nilutamide and Sevoflurane. Corneal disease [9A76-9A78] [40]
Probucol DMVZQ2M Moderate Increased risk of prolong QT interval by the combination of Nilutamide and Probucol. Coronary atherosclerosis [BA80] [40]
Clofazimine DMEBOFW Moderate Increased risk of prolong QT interval by the combination of Nilutamide and Clofazimine. Crohn disease [DD70] [40]
Mifepristone DMGZQEF Major Increased risk of prolong QT interval by the combination of Nilutamide and Mifepristone. Cushing syndrome [5A70] [41]
Pasireotide DMHM7JS Major Increased risk of prolong QT interval by the combination of Nilutamide and Pasireotide. Cushing syndrome [5A70] [41]
Osilodrostat DMIJC9X Moderate Increased risk of prolong QT interval by the combination of Nilutamide and Osilodrostat. Cushing syndrome [5A70] [40]
Lumacaftor DMCLWDJ Moderate Increased metabolism of Nilutamide caused by Lumacaftor mediated induction of CYP450 enzyme. Cystic fibrosis [CA25] [49]
Sertraline DM0FB1J Moderate Increased risk of prolong QT interval by the combination of Nilutamide and Sertraline. Depression [6A70-6A7Z] [40]
Trimipramine DM1SC8M Moderate Increased risk of prolong QT interval by the combination of Nilutamide and Trimipramine. Depression [6A70-6A7Z] [40]
Escitalopram DMFK9HG Major Increased risk of prolong QT interval by the combination of Nilutamide and Escitalopram. Depression [6A70-6A7Z] [41]
Clomipramine DMINRKW Moderate Increased risk of prolong QT interval by the combination of Nilutamide and Clomipramine. Depression [6A70-6A7Z] [40]
Doxepin DMPI98T Moderate Increased risk of prolong QT interval by the combination of Nilutamide and Doxepin. Depression [6A70-6A7Z] [40]
Maprotiline DMPWB7T Moderate Increased risk of prolong QT interval by the combination of Nilutamide and Maprotiline. Depression [6A70-6A7Z] [40]
Tetrabenazine DMYWQ0O Moderate Increased risk of prolong QT interval by the combination of Nilutamide and Tetrabenazine. Dissociative neurological symptom disorder [6B60] [40]
Deutetrabenazine DMUPFLI Moderate Increased risk of prolong QT interval by the combination of Nilutamide and Deutetrabenazine. Dystonic disorder [8A02] [40]
Ingrezza DMVPLNC Moderate Increased risk of prolong QT interval by the combination of Nilutamide and Ingrezza. Dystonic disorder [8A02] [40]
Cannabidiol DM0659E Moderate Increased risk of hepatotoxicity by the combination of Nilutamide and Cannabidiol. Epileptic encephalopathy [8A62] [40]
Pentamidine DMHZJCG Moderate Increased risk of prolong QT interval by the combination of Nilutamide and Pentamidine. Fungal infection [1F29-1F2F] [40]
Ketoconazole DMPZI3Q Moderate Increased risk of prolong QT interval by the combination of Nilutamide and Ketoconazole. Fungal infection [1F29-1F2F] [40]
Sunitinib DMCBJSR Moderate Increased risk of prolong QT interval by the combination of Nilutamide and Sunitinib. Gastrointestinal stromal tumour [2B5B] [40]
Brentuximab vedotin DMWLC57 Moderate Increased risk of hepatotoxicity by the combination of Nilutamide and Brentuximab vedotin. Hodgkin lymphoma [2B30] [50]
Fostemsavir DM50ILT Moderate Increased risk of prolong QT interval by the combination of Nilutamide and Fostemsavir. Human immunodeficiency virus disease [1C60-1C62] [40]
Saquinavir DMG814N Major Increased risk of prolong QT interval by the combination of Nilutamide and Saquinavir. Human immunodeficiency virus disease [1C60-1C62] [51]
Lopinavir DMITQS0 Moderate Increased risk of prolong QT interval by the combination of Nilutamide and Lopinavir. Human immunodeficiency virus disease [1C60-1C62] [40]
Rilpivirine DMJ0QOW Moderate Increased risk of prolong QT interval by the combination of Nilutamide and Rilpivirine. Human immunodeficiency virus disease [1C60-1C62] [40]
Mipomersen DMGSRN1 Major Increased risk of hepatotoxicity by the combination of Nilutamide and Mipomersen. Hyper-lipoproteinaemia [5C80] [52]
Teriflunomide DMQ2FKJ Major Increased risk of hepatotoxicity by the combination of Nilutamide and Teriflunomide. Hyper-lipoproteinaemia [5C80] [41]
BMS-201038 DMQTAGO Major Increased risk of hepatotoxicity by the combination of Nilutamide and BMS-201038. Hyper-lipoproteinaemia [5C80] [53]
Polyethylene glycol DM4I1JP Moderate Increased risk of ventricular arrhythmias by the combination of Nilutamide and Polyethylene glycol. Irritable bowel syndrome [DD91] [40]
Phenolphthalein DM5SICT Moderate Increased risk of ventricular arrhythmias by the combination of Nilutamide and Phenolphthalein. Irritable bowel syndrome [DD91] [41]
Crizotinib DM4F29C Major Increased risk of prolong QT interval by the combination of Nilutamide and Crizotinib. Lung cancer [2C25] [54]
Ceritinib DMB920Z Major Increased risk of prolong QT interval by the combination of Nilutamide and Ceritinib. Lung cancer [2C25] [41]
Osimertinib DMRJLAT Major Increased risk of prolong QT interval by the combination of Nilutamide and Osimertinib. Lung cancer [2C25] [55]
Selpercatinib DMZR15V Major Increased risk of prolong QT interval by the combination of Nilutamide and Selpercatinib. Lung cancer [2C25] [40]
Lumefantrine DM29GAD Major Increased risk of prolong QT interval by the combination of Nilutamide and Lumefantrine. Malaria [1F40-1F45] [38]
Halofantrine DMOMK1V Major Increased risk of prolong QT interval by the combination of Nilutamide and Halofantrine. Malaria [1F40-1F45] [56]
Hydroxychloroquine DMSIVND Moderate Increased risk of prolong QT interval by the combination of Nilutamide and Hydroxychloroquine. Malaria [1F40-1F45] [40]
Primaquine DMWQ16I Moderate Increased risk of prolong QT interval by the combination of Nilutamide and Primaquine. Malaria [1F40-1F45] [40]
Inotuzumab ozogamicin DMAC130 Moderate Increased risk of prolong QT interval by the combination of Nilutamide and Inotuzumab ozogamicin. Malignant haematopoietic neoplasm [2B33] [40]
Calaspargase pegol DMQZBXI Moderate Increased risk of hepatotoxicity by the combination of Nilutamide and Calaspargase pegol. Malignant haematopoietic neoplasm [2B33] [57]
Idelalisib DM602WT Moderate Increased risk of hepatotoxicity by the combination of Nilutamide and Idelalisib. Mature B-cell leukaemia [2A82] [58]
Arsenic trioxide DM61TA4 Major Increased risk of prolong QT interval by the combination of Nilutamide and Arsenic trioxide. Mature B-cell lymphoma [2A85] [59]
Vemurafenib DM62UG5 Major Increased risk of prolong QT interval by the combination of Nilutamide and Vemurafenib. Melanoma [2C30] [41]
LGX818 DMNQXV8 Moderate Increased risk of prolong QT interval by the combination of Nilutamide and LGX818. Melanoma [2C30] [40]
Panobinostat DM58WKG Major Increased risk of prolong QT interval by the combination of Nilutamide and Panobinostat. Multiple myeloma [2A83] [60]
Thalidomide DM70BU5 Moderate Increased risk of ventricular arrhythmias by the combination of Nilutamide and Thalidomide. Multiple myeloma [2A83] [38]
Siponimod DM2R86O Major Increased risk of ventricular arrhythmias by the combination of Nilutamide and Siponimod. Multiple sclerosis [8A40] [38]
Fingolimod DM5JVAN Major Increased risk of ventricular arrhythmias by the combination of Nilutamide and Fingolimod. Multiple sclerosis [8A40] [41]
Ozanimod DMT6AM2 Major Increased risk of ventricular arrhythmias by the combination of Nilutamide and Ozanimod. Multiple sclerosis [8A40] [61]
Romidepsin DMT5GNL Moderate Increased risk of prolong QT interval by the combination of Nilutamide and Romidepsin. Mycosis fungoides [2B01] [40]
Nilotinib DM7HXWT Major Increased risk of prolong QT interval by the combination of Nilutamide and Nilotinib. Myeloproliferative neoplasm [2A20] [41]
Dasatinib DMJV2EK Moderate Increased risk of prolong QT interval by the combination of Nilutamide and Dasatinib. Myeloproliferative neoplasm [2A20] [40]
Promethazine DM6I5GR Moderate Increased risk of prolong QT interval by the combination of Nilutamide and Promethazine. Nausea/vomiting [MD90] [40]
Granisetron DMIUW25 Moderate Increased risk of prolong QT interval by the combination of Nilutamide and Granisetron. Nausea/vomiting [MD90] [40]
Dolasetron DMMG26Z Major Increased risk of prolong QT interval by the combination of Nilutamide and Dolasetron. Nausea/vomiting [MD90] [41]
Ondansetron DMOTQ1I Moderate Increased risk of prolong QT interval by the combination of Nilutamide and Ondansetron. Nausea/vomiting [MD90] [40]
Entrectinib DMMPTLH Moderate Increased risk of prolong QT interval by the combination of Nilutamide and Entrectinib. Non-small cell lung cancer [2C25] [40]
Levomethadyl Acetate DM06HG5 Major Increased risk of prolong QT interval by the combination of Nilutamide and Levomethadyl Acetate. Opioid use disorder [6C43] [40]
Lofexidine DM1WXA6 Moderate Increased risk of prolong QT interval by the combination of Nilutamide and Lofexidine. Opioid use disorder [6C43] [40]
Rucaparib DM9PVX8 Moderate Increased risk of prolong QT interval by the combination of Nilutamide and Rucaparib. Ovarian cancer [2C73] [40]
Buprenorphine DMPRI8G Moderate Increased risk of prolong QT interval by the combination of Nilutamide and Buprenorphine. Pain [MG30-MG3Z] [40]
Triclabendazole DMPWGBR Moderate Increased risk of prolong QT interval by the combination of Nilutamide and Triclabendazole. Parasitic worm infestation [1F90] [40]
Pimavanserin DMR7IVC Moderate Increased risk of prolong QT interval by the combination of Nilutamide and Pimavanserin. Parkinsonism [8A00] [40]
Apomorphine DMX38HQ Moderate Increased risk of prolong QT interval by the combination of Nilutamide and Apomorphine. Parkinsonism [8A00] [40]
Famotidine DMRL3AB Moderate Increased risk of prolong QT interval by the combination of Nilutamide and Famotidine. Peptic ulcer [DA61] [38]
Macimorelin DMQYJIR Major Increased risk of prolong QT interval by the combination of Nilutamide and Macimorelin. Pituitary gland disorder [5A60-5A61] [62]
Lefamulin DME6G97 Major Increased risk of prolong QT interval by the combination of Nilutamide and Lefamulin. Pneumonia [CA40] [63]
Ritodrine DM4V6RL Moderate Increased risk of prolong QT interval by the combination of Nilutamide and Ritodrine. Preterm labour/delivery [JB00] [44]
Levomepromazine DMIKFEL Moderate Increased risk of prolong QT interval by the combination of Nilutamide and Levomepromazine. Psychotic disorder [6A20-6A25] [40]
Gatifloxacin DMSL679 Major Increased risk of prolong QT interval by the combination of Nilutamide and Gatifloxacin. Respiratory infection [CA07-CA4Z] [64]
Leflunomide DMR8ONJ Major Increased risk of hepatotoxicity by the combination of Nilutamide and Leflunomide. Rheumatoid arthritis [FA20] [41]
Quetiapine DM1N62C Moderate Increased risk of prolong QT interval by the combination of Nilutamide and Quetiapine. Schizophrenia [6A20] [40]
Mesoridazine DM2ZGAN Major Increased risk of prolong QT interval by the combination of Nilutamide and Mesoridazine. Schizophrenia [6A20] [41]
Thioridazine DM35M8J Major Increased risk of prolong QT interval by the combination of Nilutamide and Thioridazine. Schizophrenia [6A20] [41]
Aripiprazole DM3NUMH Moderate Increased risk of prolong QT interval by the combination of Nilutamide and Aripiprazole. Schizophrenia [6A20] [38]
Iloperidone DM6AUFY Major Increased risk of prolong QT interval by the combination of Nilutamide and Iloperidone. Schizophrenia [6A20] [41]
Paliperidone DM7NPJS Moderate Increased risk of prolong QT interval by the combination of Nilutamide and Paliperidone. Schizophrenia [6A20] [40]
Perphenazine DMA4MRX Moderate Increased risk of prolong QT interval by the combination of Nilutamide and Perphenazine. Schizophrenia [6A20] [40]
Trifluoperazine DMKBYWI Moderate Increased risk of prolong QT interval by the combination of Nilutamide and Trifluoperazine. Schizophrenia [6A20] [40]
Risperidone DMN6DXL Moderate Increased risk of prolong QT interval by the combination of Nilutamide and Risperidone. Schizophrenia [6A20] [40]
Asenapine DMSQZE2 Moderate Increased risk of prolong QT interval by the combination of Nilutamide and Asenapine. Schizophrenia [6A20] [40]
Pimozide DMW83TP Major Increased risk of prolong QT interval by the combination of Nilutamide and Pimozide. Schizophrenia [6A20] [40]
Vardenafil DMTBGW8 Moderate Increased risk of prolong QT interval by the combination of Nilutamide and Vardenafil. Sexual dysfunction [HA00-HA01] [40]
Trabectedin DMG3Y89 Moderate Increased risk of hepatotoxicity by the combination of Nilutamide and Trabectedin. Solid tumour/cancer [2A00-2F9Z] [40]
LEE011 DMMX75K Major Increased risk of prolong QT interval by the combination of Nilutamide and LEE011. Solid tumour/cancer [2A00-2F9Z] [41]
Vandetanib DMRICNP Major Increased risk of prolong QT interval by the combination of Nilutamide and Vandetanib. Solid tumour/cancer [2A00-2F9Z] [41]
Doxorubicin DMVP5YE Moderate Increased risk of prolong QT interval by the combination of Nilutamide and Doxorubicin. Solid tumour/cancer [2A00-2F9Z] [40]
Pitolisant DM8RFNJ Moderate Increased risk of prolong QT interval by the combination of Nilutamide and Pitolisant. Somnolence [MG42] [40]
Telavancin DM58VQX Moderate Increased risk of prolong QT interval by the combination of Nilutamide and Telavancin. Staphylococcal/streptococcal disease [1B5Y] [40]
Naltrexone DMUL45H Moderate Increased risk of hepatotoxicity by the combination of Nilutamide and Naltrexone. Substance abuse [6C40] [65]
Lenvatinib DMB1IU4 Moderate Increased risk of prolong QT interval by the combination of Nilutamide and Lenvatinib. Thyroid cancer [2D10] [40]
Cabozantinib DMIYDT4 Major Increased risk of prolong QT interval by the combination of Nilutamide and Cabozantinib. Thyroid cancer [2D10] [40]
Papaverine DMCA9QP Major Increased risk of prolong QT interval by the combination of Nilutamide and Papaverine. Tonus and reflex abnormality [MB47] [66]
Tizanidine DMR2IQ4 Moderate Increased risk of prolong QT interval by the combination of Nilutamide and Tizanidine. Tonus and reflex abnormality [MB47] [40]
Tacrolimus DMZ7XNQ Moderate Increased risk of prolong QT interval by the combination of Nilutamide and Tacrolimus. Transplant rejection [NE84] [40]
Trimeprazine DMEMV9D Moderate Increased risk of prolong QT interval by the combination of Nilutamide and Trimeprazine. Vasomotor/allergic rhinitis [CA08] [40]
Procainamide DMNMXR8 Major Increased risk of prolong QT interval by the combination of Nilutamide and Procainamide. Ventricular tachyarrhythmia [BC71] [41]
Propafenone DMPIBJK Moderate Increased risk of prolong QT interval by the combination of Nilutamide and Propafenone. Ventricular tachyarrhythmia [BC71] [40]
Flecainide DMSQDLE Moderate Increased risk of prolong QT interval by the combination of Nilutamide and Flecainide. Ventricular tachyarrhythmia [BC71] [40]
⏷ Show the Full List of 145 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Docusate sodium E00563 23673837 Surfactant
Beta-D-lactose E00099 6134 Diluent; Dry powder inhaler carrier; Lyophilization aid
Calcium stearate E00244 15324 lubricant
Lactose monohydrate E00393 104938 Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate E00208 11177 lubricant
Povidone E00667 Not Available Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Talc E00520 16211421 Anticaking agent; Diluent; Glidant; lubricant
Vinylpyrrolidone E00668 Not Available Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
⏷ Show the Full List of 8 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Nilutamide 150 mg tablet 150 mg Oral Tablet Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2864).
2 Drug insight: role of the androgen receptor in the development and progression of prostate cancer. Nat Clin Pract Oncol. 2007 Apr;4(4):236-44.
3 Critical Evaluation of Human Oral Bioavailability for Pharmaceutical Drugs by Using Various Cheminformatics Approaches
4 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
5 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
6 CX3CR1 is expressed by prostate epithelial cells and androgens regulate the levels of CX3CL1/fractalkine in the bone marrow: potential role in prostate cancer bone tropism. Cancer Res. 2008 Mar 15;68(6):1715-22.
7 Nilutamide inhibits mephenytoin 4-hydroxylation in untreated male rats and in human liver microsomes. Xenobiotica. 1991 Dec;21(12):1559-70.
8 Generation of free radicals during the reductive metabolism of nilutamide by lung microsomes: possible role in the development of lung lesions in patients treated with this anti-androgen. Biochem Pharmacol. 1992 Feb 4;43(3):654-7.
9 High-dose rabeprazole/amoxicillin therapy as the second-line regimen after failure to eradicate H. pylori by triple therapy with the usual doses of a proton pump inhibitor, clarithromycin and amoxicillin. Hepatogastroenterology. 2003 Nov-Dec;50(54):2274-8.
10 Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes. Arch Biochem Biophys. 1997 Oct 1;346(1):161-9.
11 Cytochrome P450 pharmacogenetics and cancer. Oncogene. 2006 Mar 13;25(11):1679-91.
12 CYP2C19*17 is associated with decreased breast cancer risk. Breast Cancer Res Treat. 2009 May;115(2):391-6.
13 Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
14 Cytochromes of the P450 2C subfamily are the major enzymes involved in the O-demethylation of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol. 1995 Dec;353(1):116-21.
15 Diclofenac and its derivatives as tools for studying human cytochromes P450 active sites: particular efficiency and regioselectivity of P450 2Cs. Biochemistry. 1999 Oct 26;38(43):14264-70.
16 A mechanistic approach to antiepileptic drug interactions. Ann Pharmacother. 1998 May;32(5):554-63.
17 Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology. 2001 Feb;120(2):525-33.
18 Possible involvement of multiple human cytochrome P450 isoforms in the liver metabolism of propofol. Br J Anaesth. 1998 Jun;80(6):788-95.
19 Kinetics of anthracycline antibiotic free radical formation and reductive glycosidase activity. Arch Biochem Biophys. 1983 May;223(1):68-75.
20 Lack of mechanism-based inactivation of rat hepatic microsomal cytochromes P450 by doxorubicin. Can J Physiol Pharmacol. 1999 Aug;77(8):589-97.
21 Role of cytochrome P450 reductase in nitrofurantoin-induced redox cycling and cytotoxicity. Free Radic Biol Med. 2008 Mar 15;44(6):1169-79.
22 Polymorphisms in cytochrome P450 oxidoreductase and its effect on drug metabolism and efficacy. Pharmacogenet Genomics. 2017 Sep;27(9):337-346.
23 On the mechanism of the inactivation of the major phenobarbital-inducible isozyme of rat liver cytochrome P-450 by chloramphenicol. J Biol Chem. 1985 Jul 15;260(14):8397-403.
24 Creatinine sulfate/esculoside/hesperidin methyl chalcone/menadiol sodium phosphate/tranexamic acid actions.
25 Characterization of the enzymes involved in the in vitro metabolism of amrubicin hydrochloride. Xenobiotica. 2005 Dec;35(12):1121-33.
26 Flavin-containing reductase: new perspective on the detoxification of nitrobenzodiazepine. Expert Opin Drug Metab Toxicol. 2010 Aug;6(8):967-81.
27 Dehydroepiandrosterone, glucose-6-phosphate dehydrogenase, and longevity. Ageing Res Rev. 2004 Apr;3(2):171-87.
28 Androgen receptor as a target in androgen-independent prostate cancer. Urology. 2002 Sep;60(3 Suppl 1):132-8; discussion 138-9.
29 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
30 Molecular mechanism of androgen action. Trends Endocrinol Metab. 1998 Oct 1;9(8):317-24.
31 Ouellet M, Percival MD: Effect of inhibitor time-dependency on selectivity towards cyclooxygenase isoforms. Biochem J. 1995 Feb 15;306 ( Pt 1):247-51.
32 Androgen receptor overexpression induces tamoxifen resistance in human breast cancer cells. Breast Cancer Res Treat. 2010 May;121(1):1-11.
33 The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
34 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
35 Expression of androgen receptor on fibroblast and hepatocyte of rats after deep second-degree burn caused by scalding. Sichuan Da Xue Xue Bao Yi Xue Ban. 2005 May;36(3):362-4.
36 An orally active selective androgen receptor modulator is efficacious on bone, muscle, and sex function with reduced impact on prostate. Endocrinology. 2007 Jan;148(1):363-73.
37 Benoist G, van Oort I, et al "Drug-drug interaction potential in men treated with enzalutamide: Mind the gap." Br J Clin Pharmacol 0 (2017): epub. [PMID: 28881501]
38 Cerner Multum, Inc. "Australian Product Information.".
39 Product Information. Tibsovo (ivosidenib). Agios Pharmaceuticals, Cambridge, MA.
40 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
41 Canadian Pharmacists Association.
42 Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
43 Product Information. Arcapta Neohaler (indacaterol). Novartis Pharmaceuticals, East Hanover, NJ.
44 Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32. [PMID: 7042176]
45 Ball P "Quinolone-induced QT interval prolongation: a not-so-unexpected class effect." J Antimicrob Chemother 45 (2000): 557-9. [PMID: 10797074]
46 Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
47 Eggleston W, Clark KH, Marraffa JM "Loperamide abuse associated with cardiac dysrhythmia and death." Ann Emerg Med 69 (2017): 83-6. [PMID: 27140747]
48 Hanci V, Aydin M, Yurtlu BS, et.al "Anesthesia induction with sevoflurane and propofol: evaluation of P-wave dispersion, QT and corrected QT intervals." Kaohsiung J Med Sci 26 (2010): 470-7. [PMID: 20837343]
49 Cerner Multum, Inc. "Canadian Product Information.".
50 Product Information. Adcetris (brentuximab vedotin). Seattle Genetics Inc, Bothell, WA.
51 Anson BD, Weaver JG, Ackerman MJ, et al. "Blockade of HERG channels by HIV protease inhibitors." Lancet 365 (2005): 682-686. [PMID: 15721475]
52 Product Information. Kynamro (mipomersen). Genzyme Corporation, Cambridge, MA.
53 Product Information. Juxtapid (lomitapide). Aegerion Pharmaceuticals Inc, Cambridge, MA.
54 Product Information. Xalkori (crizotinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
55 Product Information. Tagrisso (osimertinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
56 Abernethy DR, Wesche DL, Barbey JT, et al. "Stereoselective halofantrine disposition and effect: concentration-related QTc prolongation." Br J Clin Pharmacol 51 (2001): 231-7. [PMID: 11298069]
57 Al-Nawakil C, Willems L, Mauprivez C, et.al "Successful treatment of l-asparaginase-induced severe acute hepatotoxicity using mitochondrial cofactors." Leuk Lymphoma 55 (2014): 1670-4. [PMID: 24090500]
58 Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
59 Ohnishi K, Yoshida H, Shigeno K, et al. "Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia." Ann Intern Med 133 (2000): 881-5. [PMID: 11103058]
60 Product Information. Farydak (panobinostat). Novartis Pharmaceuticals, East Hanover, NJ.
61 Product Information. Zeposia (ozanimod). Celgene Corporation, Summit, NJ.
62 Product Information. Macrilen (macimorelin). Aeterna Zentaris, Charleston, SC.
63 Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
64 Ansari SR, Chopra N "Gatifloxacin and Prolonged QT Interval." Am J Med Sci 327 (2004): 55-6. [PMID: 14722399]
65 Product Information. ReVia (naltrexone). DuPont Pharmaceuticals, Wilmington, DE.
66 Goto M, Sato M, Kitzazawa H, et.al "Papaverine-induced QT interval prolongation and ventricular fibrillation in a patient with a history of drug-induced QT prolongation." Intern Med 53 (2014): 1629-31. [PMID: 25088875]